Prognostic impact of somatic mutations among patients with pleural and peritoneal mesothelioma

September 17, 2026 | Comments Off on Prognostic impact of somatic mutations among patients with pleural and peritoneal mesothelioma

NPJ Precision Oncology 2026 July 9 [Link] Justin M Bader, Ankit Dhiman, Nicole Aguirre, Kwasi Ansere Ofori, Princy Gupta, Hannah Qin, Anup Sharma, Owen Mitchell, Melissa Y Tjota, Aliya N…

Multicystic peritoneal mesothelioma mimicking recurrent pseudomyxoma peritonei

September 16, 2026 | Comments Off on Multicystic peritoneal mesothelioma mimicking recurrent pseudomyxoma peritonei

Journal of Surgical Case Reports 2026 July 7 [Link] Alessia Scarton, Marco Tonello, Elisa Pizzolato, Carola Cenzi, Ivana Cataldo, Vasileios Mourmouras, Pierluigi Pilati, Antonio Sommariva Abstract Multicystic peritoneal mesothelioma (MCPM)…

BAP1 Loss Might Be a Predictive Biomarker for Immunotherapy Response in Pleural Mesothelioma

September 15, 2026 | Comments Off on BAP1 Loss Might Be a Predictive Biomarker for Immunotherapy Response in Pleural Mesothelioma

Thoracic Cancer 2026 July [Link] Reina Imase, Rie Sakakibara, Susumu Kirimura, Hironori Ishibashi, Kenichi Okubo, Yasunari Miyazaki Abstract Introduction: Reliable predictive biomarkers for immune checkpoint inhibitors (ICIs) in pleural mesothelioma…

Protocol for Mesothelioma Observational study of Risk prediction and Generation of paired benign-meso tissue samples, Including a Nested MRI Substudy (Meso-ORIGINS)

September 14, 2026 | Comments Off on Protocol for Mesothelioma Observational study of Risk prediction and Generation of paired benign-meso tissue samples, Including a Nested MRI Substudy (Meso-ORIGINS)

BMJ Open Respiratory Research 2026 July 1 [Link] Mark D J Neilly, Alexandrea MacPherson, Laura Alexander, Nicola Walker, Caroline Kelly, Joshua Roche, Emad Abugassa, Liam Allan, Adeel Ashraf, Avinash Aujayeb,…

From Ascites to Malignant Peritoneal Mesothelioma: The Diagnostic Workup of a Rare Tumor

September 11, 2026 | Comments Off on From Ascites to Malignant Peritoneal Mesothelioma: The Diagnostic Workup of a Rare Tumor

Cancer Diagnosis & Prognosis 2026 July 1 [Link] Mirko Nastasi, Chiara Ferrante, Giuliana Michelis, Enrica Branca, Manuel Ventura, Silvia Novello, Emanuela Laurita Abstract Background/aim: Ascites is a common clinical manifestation…

Long-Term Disease Control With Second-Line Nivolumab Monotherapy in Malignant Pleural Mesothelioma: A Case Report

September 10, 2026 | Comments Off on Long-Term Disease Control With Second-Line Nivolumab Monotherapy in Malignant Pleural Mesothelioma: A Case Report

Cureus 2026 June 1 [Link] Shohei Otsuka, Kei Hiraoka, Nozomu Iwashiro Abstract Nivolumab is recommended as second-line therapy for malignant pleural mesothelioma (MPM); however, durable responses remain uncommon. In addition,…

Impact of CD73/CD155 Expression on Survival in Resected Epithelial Pleural Mesothelioma: A Retrospective Single-center Study

September 9, 2026 | Comments Off on Impact of CD73/CD155 Expression on Survival in Resected Epithelial Pleural Mesothelioma: A Retrospective Single-center Study

In Vivo 2026 July-August [Link] Yusuke Nabe, Yasuhiro Fujita, Teppei Hashimoto, Kanji Tanaka, Takehiko Manabe, Katsuma Yoshimatsu, Yukiko Nemoto, Natsumasa Nishizawa, Rintaro Oyama, Yohei Honda, Masataka Mori, Hiroki Matsumiya, Masatoshi…

Case Report: Tislelizumab combined with bevacizumab in the treatment of primary malignant pericardial mesothelioma

September 8, 2026 | Comments Off on Case Report: Tislelizumab combined with bevacizumab in the treatment of primary malignant pericardial mesothelioma

Frontiers in Oncology 2026 June 16 [Link] Zijuan Liu, Yating Yan, Caihong Jiang Abstract Background: Primary malignant pericardial mesothelioma (PMPM) is an exceedingly rare and highly malignant tumor that originates…

Outcomes of Platinum Plus Pemetrexed and Treatment Patterns Following First-Line Nivolumab and Ipilimumab in Pleural Mesothelioma: Real-World Results From the German MesoNet Study

September 7, 2026 | Comments Off on Outcomes of Platinum Plus Pemetrexed and Treatment Patterns Following First-Line Nivolumab and Ipilimumab in Pleural Mesothelioma: Real-World Results From the German MesoNet Study

Clinical Lung Cancer 2026 July 2026 July [Link] Rajiv Shah, Eva L Buchmeier, Hans-Georg Kopp, Frank Griesinger, Martin Reck, Daniel C Christoph, Jonas Kuon, Nikolaj Frost, Christian Grohé, Martin Faehling,…

Outcomes of Platinum Plus Pemetrexed and Treatment Patterns Following First-Line Nivolumab and Ipilimumab in Pleural Mesothelioma: Real-World Results From the German MesoNet Study

September 4, 2026 | Comments Off on Outcomes of Platinum Plus Pemetrexed and Treatment Patterns Following First-Line Nivolumab and Ipilimumab in Pleural Mesothelioma: Real-World Results From the German MesoNet Study

Clinical Lung Cancer 2026 July [Link] Rajiv Shah, Eva L Buchmeier, Hans-Georg Kopp, Frank Griesinger, Martin Reck, Daniel C Christoph, Jonas Kuon, Nikolaj Frost, Christian Grohé, Martin Faehling, Felix C…

Categories